Which has higher earnings and valuation, KZIA or ACXP?

Acurx Pharmaceuticals has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 792.33 -$13.41M N/A N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is KZIA or ACXP more profitable?

Novogen's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Acurx Pharmaceuticals N/A -153.92% -101.69%

Is ACXP or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts recommend TXMD or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,906.47%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, RKTO or ACXP?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is RKTO or ACXP more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Acurx Pharmaceuticals N/A -153.92% -101.69%

Acurx Pharmaceuticals (ACXP) Competitors

$1.54 -0.01 (-0.32%)

As of 10:14 AM Eastern

Compare

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

Should you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Novogen (KZIA), Aytu BioPharma (AYTU), Neuphoria Therapeutics (NEUP), TherapeuticsMD (TXMD), and Rocket One Inc. Common Stock (RKTO). These companies are all part of the "pharmaceutical products" industry.

How does Acurx Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Novogen had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for Novogen and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Novogen's score of 1.87 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Very Positive
Acurx Pharmaceuticals	Very Positive

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market.

Novogen's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Acurx Pharmaceuticals has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	792.33	-$13.41M	N/A	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

30.9% of Novogen shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novogen currently has a consensus price target of $25.80, indicating a potential upside of 79.09%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,906.47%. Given Acurx Pharmaceuticals' higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Novogen beats Acurx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 390.87%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,906.47%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Aytu BioPharma's score of 1.87 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Acurx Pharmaceuticals	Very Positive

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Aytu BioPharma and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

In the previous week, Neuphoria Therapeutics had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Neuphoria Therapeutics' score of 0.57 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
Neuphoria Therapeutics	Positive

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neuphoria Therapeutics' return on equity of -76.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Neuphoria Therapeutics has higher revenue and earnings than Acurx Pharmaceuticals. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Neuphoria Therapeutics	$15.65M	1.54	-$370K	-$11.06	N/A

Acurx Pharmaceuticals currently has a consensus price target of $31.00, indicating a potential upside of 1,906.47%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 370.32%. Given Acurx Pharmaceuticals' higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its stock price is 309% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Summary

Neuphoria Therapeutics beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

TherapeuticsMD has a net margin of 5.34% compared to Acurx Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,906.47%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TherapeuticsMD has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Acurx Pharmaceuticals	Very Positive

TherapeuticsMD has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.39	-$570K	$0.06	36.50
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TherapeuticsMD beats Acurx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Acurx Pharmaceuticals' return on equity of -153.92% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Rocket One Inc. Common Stock and Rocket One Inc. Common Stock both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Rocket One Inc. Common Stock's score of 0.94 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Positive
Acurx Pharmaceuticals	Very Positive

Rocket One Inc. Common Stock currently has a consensus target price of $5.00, suggesting a potential upside of 426.37%. Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,906.47%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Rocket One Inc. Common Stock has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market.

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Acurx Pharmaceuticals beats Rocket One Inc. Common Stock on 8 of the 10 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.64M	$3.66B	$6.80B	$12.55B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.38	21.33	27.42	25.27
Price / Sales	N/A	343.41	542.60	102.53
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.75	8.81	11.00	6.57
Net Income	-$7.97M	$23.81M	$3.57B	$336.82M
7 Day Performance	5.10%	3.89%	2.69%	2.31%
1 Month Performance	-19.95%	3.97%	1.85%	-0.12%
1 Year Performance	-84.27%	68.75%	36.85%	30.30%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	3.2476 of 5 stars	$1.55 -0.3%	$31.00 +1,906.5%	-84.8%	$6.64M	N/A	N/A	3	Positive News Gap Up
KZIA Novogen	2.42 of 5 stars	$14.69 +4.9%	$23.75 +61.7%	+124.6%	$24.28M	$42K	N/A	12	Positive News Analyst Forecast
AYTU Aytu BioPharma	3.2657 of 5 stars	$2.24 -0.4%	$9.83 +339.0%	-1.4%	$24.04M	$56.60M	N/A	160	Positive News
NEUP Neuphoria Therapeutics	3.4389 of 5 stars	$4.36 -1.8%	$21.00 +381.7%	-38.5%	$23.54M	$15.65M	N/A	N/A	Short Interest Decrease
TXMD TherapeuticsMD	1.6774 of 5 stars	$2.00 flat	N/A	+90.5%	$23.15M	$3.35M	33.33	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

How does Acurx Pharmaceuticals compare to Novogen?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

How does Acurx Pharmaceuticals compare to Novogen?

Does the media refer more to KZIA or ACXP?

Which has more volatility & risk, KZIA or ACXP?

Is KZIA or ACXP more profitable?

Which has higher earnings and valuation, KZIA or ACXP?

Do institutionals & insiders have more ownership in KZIA or ACXP?

Do analysts rate KZIA or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Which has more risk & volatility, AYTU or ACXP?

Which has higher earnings & valuation, AYTU or ACXP?

Do analysts recommend AYTU or ACXP?

Is AYTU or ACXP more profitable?

Does the media favor AYTU or ACXP?

Do insiders and institutionals believe in AYTU or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Does the media refer more to ACXP or NEUP?

Do insiders & institutionals believe in ACXP or NEUP?

Is ACXP or NEUP more profitable?

Which has better valuation and earnings, ACXP or NEUP?

Do analysts prefer ACXP or NEUP?

Which has more risk & volatility, ACXP or NEUP?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Is TXMD or ACXP more profitable?

Do analysts recommend TXMD or ACXP?

Which has more volatility & risk, TXMD or ACXP?

Does the media prefer TXMD or ACXP?

Which has higher valuation and earnings, TXMD or ACXP?

Do institutionals & insiders have more ownership in TXMD or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Is RKTO or ACXP more profitable?

Does the media prefer RKTO or ACXP?

Do analysts rate RKTO or ACXP?

Which has stronger earnings & valuation, RKTO or ACXP?

Which has more risk & volatility, RKTO or ACXP?

Do institutionals and insiders have more ownership in RKTO or ACXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools